Tags

Type your tag names separated by a space and hit enter

Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.
J Pediatr 2008; 152(3):394-9JPed

Abstract

OBJECTIVE

This secondary analysis evaluated the efficacy of modafinil in children and adolescents by subtype of attention-deficit/hyperactivity disorder (ADHD) using pooled data from 3 double-blind, placebo-controlled studies.

STUDY DESIGN

The patients were boys and girls age 6 to 17 years. ADHD subtype diagnoses (ie, inattentive, hyperactive-impulsive, combined) were based on criteria published in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Patients received modafinil (170 to 425 mg) or placebo once daily for 7 to 9 weeks. Efficacy assessment used the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) School and Home Versions, Clinical Global Impression of Improvement scale (CGI-I), and Conners' Parent Rating Scale-Revised: Short Form (CPRS-R:S).

RESULTS

A total of 638 patients received modafinil (n = 423) or placebo (n = 215). The inattentive, hyperactive-impulsive, and combined subtypes included 187 (30%), 27 (4%), and 403 (65%) patients, respectively. Modafinil (vs placebo) significantly improved mean total scores for the ADHD-RS-IV School and Home Versions for the inattentive (change from baseline: School, modafinil, -15.7, placebo, -7.1; Home, modafinil, -13.8, placebo, -5.9) and combined subtypes (School, -16.5 vs -8.8; Home, -15.7 vs -7.6). Modafinil was associated with greater improvements on the CGI-I and improved CPRS-R:S subscale scores in inattentive and combined subtypes.

CONCLUSIONS

Modafinil improved ADHD symptoms and behaviors in patients with the inattentive and combined subtypes as determined by teachers, investigators, and parents.

Authors+Show Affiliations

Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA, USA.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18280848

Citation

Biederman, Joseph, and Steven R. Pliszka. "Modafinil Improves Symptoms of Attention-deficit/hyperactivity Disorder Across Subtypes in Children and Adolescents." The Journal of Pediatrics, vol. 152, no. 3, 2008, pp. 394-9.
Biederman J, Pliszka SR. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents. J Pediatr. 2008;152(3):394-9.
Biederman, J., & Pliszka, S. R. (2008). Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents. The Journal of Pediatrics, 152(3), pp. 394-9. doi:10.1016/j.jpeds.2007.07.052.
Biederman J, Pliszka SR. Modafinil Improves Symptoms of Attention-deficit/hyperactivity Disorder Across Subtypes in Children and Adolescents. J Pediatr. 2008;152(3):394-9. PubMed PMID: 18280848.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents. AU - Biederman,Joseph, AU - Pliszka,Steven R, Y1 - 2007/10/24/ PY - 2006/06/12/received PY - 2007/06/20/revised PY - 2007/07/27/accepted PY - 2008/2/19/pubmed PY - 2008/3/19/medline PY - 2008/2/19/entrez SP - 394 EP - 9 JF - The Journal of pediatrics JO - J. Pediatr. VL - 152 IS - 3 N2 - OBJECTIVE: This secondary analysis evaluated the efficacy of modafinil in children and adolescents by subtype of attention-deficit/hyperactivity disorder (ADHD) using pooled data from 3 double-blind, placebo-controlled studies. STUDY DESIGN: The patients were boys and girls age 6 to 17 years. ADHD subtype diagnoses (ie, inattentive, hyperactive-impulsive, combined) were based on criteria published in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Patients received modafinil (170 to 425 mg) or placebo once daily for 7 to 9 weeks. Efficacy assessment used the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) School and Home Versions, Clinical Global Impression of Improvement scale (CGI-I), and Conners' Parent Rating Scale-Revised: Short Form (CPRS-R:S). RESULTS: A total of 638 patients received modafinil (n = 423) or placebo (n = 215). The inattentive, hyperactive-impulsive, and combined subtypes included 187 (30%), 27 (4%), and 403 (65%) patients, respectively. Modafinil (vs placebo) significantly improved mean total scores for the ADHD-RS-IV School and Home Versions for the inattentive (change from baseline: School, modafinil, -15.7, placebo, -7.1; Home, modafinil, -13.8, placebo, -5.9) and combined subtypes (School, -16.5 vs -8.8; Home, -15.7 vs -7.6). Modafinil was associated with greater improvements on the CGI-I and improved CPRS-R:S subscale scores in inattentive and combined subtypes. CONCLUSIONS: Modafinil improved ADHD symptoms and behaviors in patients with the inattentive and combined subtypes as determined by teachers, investigators, and parents. SN - 1097-6833 UR - https://www.unboundmedicine.com/medline/citation/18280848/Modafinil_improves_symptoms_of_attention_deficit/hyperactivity_disorder_across_subtypes_in_children_and_adolescents_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-3476(07)00748-2 DB - PRIME DP - Unbound Medicine ER -